Statistical aspects of bioequivalence testing between two medicinal products

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 1-2, 2005, Pages 41-46

  Zintzaras, E ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Add on; Bioequivalence; Crossover; Curve comparison; Individual bioequivalence; Outlier; Period effect; Sample size; Sequence effect

Indexed keywords

DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; IN VIVO STUDY; NONPARAMETRIC TEST; PARAMETRIC TEST; SAMPLING; STATISTICAL ANALYSIS;

EID: 21344453782     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03226406     Document Type: Article

References (24)

1. CPMP/EWP/QWP/1401/98 (2001): Note for Guidance on the Investigation of Bioavailability and Bioequivalence.
2. Zintzaras E. and Bouka P. (1999): Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis. Eur J Drug Metab Pharmacokinet, 24, 225-232.
3. Food and Drug Administration Center for Drug Evaluation and Research (2001): Guidance for Industry: Statistical Approaches to Establishing Bioequivalence.
4. Chow S.C. and Liu J.P. (1992): Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker.
5. Anderson S and Hauck W.W. (1990): Consideraation of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics, 18, 259-273.
6. Bolton S. (1997): Pharmaceutical Statistics. New York. Marcel Dekker.
7. Zintzaras E (2000): The existence of sequence effect in cross-over Bioequivalence trials. Eur. J Drug Metab Pharmacokinet, 25, 241-244.
8. Shuirmann D.J. (1987): A comparison of the two one-sided tests procedure and the power approach for assessing the bioequivalence of average bioavailability. J. Pharmacokinet. Biopharm., 15, 657-680.
9. Hauschke D. (1990): A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharm Ther Toxic, 28, 72-78.
10. Jones B. and Kenward M.G. (1995): Design and Analysis of Cross-Over Trials. London: Chapman and Hall.
11. Melander H. (1991): Problems and Possibilities with the Add-On Subject Design. Bio-International 1991.
12. Chen M.L. (1997): Individual bioequivalence-a regulatory update. Journal of Biopharmaceutical Statistics, 7, 5-11.
13. Endrenyi L, Amidon G.L., Midha K.K. Skelly JP. (1998): Individual bioequivalence: attractive in principle, difficult in practice. Pharm Res, 15, 1321-1325
14. Schall R. and Williams R.L. (1996) Towards a practical strategy for assessing individual bioequivalence. J Pharmacok Biopharm, 24, 133-152.
15. Shah VP, Tsong Y, Sathe P, Liu JP (1998) In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res. 15, 889-896.
16. Zintzaras E. Bouka P. and A. Kowald (2002): Biometrical evaluation of bioequivalence trials using a bootstrap individual direct curve comparison method. Eur J Drug Metab Pharmacokinet, 27, 11-16.
17. Polli JE, McLean AM. (2001): Novel Direct Curve Comparison Metrics for Bioequivalence Pharm Res, 18, 734-741.
18. Ormsby E. (1994): Statistical Methods in Bioequivalence. London. CRC Press Inc.
19. Diletti E. et al. (1991): Sample size determination for bioequivalencce assessment by means of confidence intervals. Int J Clin Pharm Ther Toxic, 29, 1-8.
20. Rescigno A. (1992): Bioequivalence. Pharm. Res., 9, 925-928.
21. Hauck W.W. and Anderson S. (1992): Types of Bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol, 30, 181-187.
22. Chen ML, Lesko LJ. (2001): Individual Bioequivalence revisited Clin Pharmacokinet, 40, 701-706.
23. Chen ML. Patnaik R, Hauck WW, Shuirmann DJ, Hyslop T, William R. (2000): An Individual Bioequivalence Criterion: regulatory considerations. Stat Med, 19, 2821-2842.
24. Hauck W.W, Hyslop T, Chen ML, Patnaik R, William R. (2000): Subject-by-Formulation Interaction in Bioequivalence: Conseptual and Statistical Issues Pharm Research, 17, 375-380.